NovaBridge CMO plans sale of 3,569 shares

NovaBridge Biosciences (NBP) discloses that Chief Medical Officer Dennis Phillip Andrew filed a Rule 144 notice to sell 3,569 shares of common stock through Citigroup Global Markets on September 18, 2026 on NASDAQ.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) discloses that Chief Medical Officer Dennis Phillip Andrew filed a Rule 144 notice to sell 3,569 shares of common stock through Citigroup Global Markets on September 18, 2026 on NASDAQ. The shares relate to restricted stock vesting, with 10,302 shares noted as securities to be sold from compensation vesting on the same date. Over the prior three months, he reported selling 3,693 shares of common stock.

Key Figures

Planned shares to be sold: 3,569 shares Securities to be sold from restricted stock vesting: 10,302 shares Shares sold in past three months: 3,693 shares +3 more

6 metrics

Planned shares to be sold 3,569 shares Common stock sale through Citigroup Global Markets on September 18, 2026

Securities to be sold from restricted stock vesting 10,302 shares Common stock from Restricted Stock Vesting and Compensation on September 18, 2026

Shares sold in past three months 3,693 shares Common stock sale by Dennis Phillip Andrew on June 18, 2026

Aggregate value of planned sale $5,798.55 Aggregate sale amount associated with the 3,569-share planned sale

Aggregate value of prior sale $5,593.05 Aggregate sale amount for 3,693 shares sold on June 18, 2026

Date of notice September 18, 2026 Filing date of the Rule 144 notice

Key Terms

Rule 144, Restricted Stock Vesting, restricted stock units

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common Stock | 09/18/2026 | Restricted Stock Vesting |"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

restricted stock units financial

"Shares to be sold were from the vesting of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovaBridge Biosciences (NBP) disclose in this Form 144 filing?

The filing states that Chief Medical Officer Dennis Phillip Andrew filed a Rule 144 notice to sell 3,569 shares of NovaBridge Biosciences common stock through Citigroup Global Markets on September 18, 2026.

How many NovaBridge Biosciences (NBP) shares are associated with the planned sale?

The notice covers a planned sale of 3,569 shares of common stock. A related section lists 10,302 shares of common stock as securities to be sold arising from restricted stock vesting dated September 18, 2026.

What is the reason for the NovaBridge Biosciences (NBP) share sale?

The remarks state that the shares to be sold were from the vesting of restricted stock units to cover tax obligations, indicating the sale is linked to equity compensation vesting and associated taxes.

Which broker is handling the planned NovaBridge Biosciences (NBP) share sale?

The notice lists Citigroup Global Markets, Inc., located at 390 Greenwich St., New York, NY, as the broker for the planned sale of 3,569 shares of NovaBridge Biosciences common stock.

What NovaBridge Biosciences (NBP) stock sales were made in the past three months?

Over the prior three months, Dennis Phillip Andrew reported selling 3,693 shares of NovaBridge Biosciences common stock on June 18, 2026, with an aggregate sale value of $5,593.05.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 11:57 AM Accepted by SEC EDGAR 09/18/2026 - 11:57 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002089237
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NovaBridge Biosciences
SEC File Number	001-39173
Address of Issuer	SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MARYLAND 20850
Phone	(301) 670 2800
Name of Person for Whose Account the Securities are To Be Sold	Dennis Phillip Andrew
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Medical Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Citigroup Global Markets, Inc. 390 Greenwich St. New York NY 10013	3569	5798.55	265377891	09/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/18/2026	Restricted Stock Vesting	NovaBridge Biosciences			10302	09/18/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Dennis Phillip Andrew SUITE 400, 2440 RESEARCH BLVD Rockville MD 20850	Common Stock	06/18/2026	3693	5593.05

144: Remarks and Signature

Remarks	Shares to be sold were from the vesting of the restricted stock units to cover tax obligations. .
Date of Notice	09/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)